A new analysis based on data from the Phase III CLARITY AD trial of Leqembi (lecanemab) has been published in Neurology and Therapy.
The data, which estimate the societal value of the novel Alzheimer’s disease (AD) therapy, could prove useful in negotiations with payers and reimbursement agencies.
Developed by Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523), Leqembi broke new ground in the treatment of AD, with approval in the USA following significant clinical results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze